Heme Arginate Suppresses Cardiac Lesions and Hypertrophy in Deoxycorticosterone Acetate-Salt Hypertension
Authors:
- 1 July 2009
- journal article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 234 (7) , 764-778
Abstract
In hypertension, elevated levels of oxidative/inflammatory mediators including nuclear factor kappaB (NF-κB), activating protein (AP-1), c-Jun-NH2-terminal kinase (JNK), and cell-regulatory proteins such as transforming growth factor beta (TGF-β), trigger the mobilization of extracellular matrix (ECM) leading to fibrosis, hypertrophy and impairment of cardiac function. Although the heme oxygenase (HO) system is cytoprotective, its effects on cardiac fibrosis and hypertrophy in deoxycorticosterone acetate (DOCA-salt) hypertension are not completely elucidated. Here, we report cardioprotection by the HO inducer, heme arginate against histopathological lesions in DOCA-hypertension. Treatment with heme arginate restored physiological blood pressure, and abated cardiac hypertrophy (3.75 ± 0.12 vs. 3.19 ± 0.09 g/kg body wt; n =16, P < 0.01), left-to-right ventricular ratio (6.67 ± 0.62 vs. 4.39 ± 0.63; n = 16, P < 0.01), left ventricular mass (2.48 ± 0.14 vs. 2.01 ± 0.09 g/kg body wt; n = 16, P < 0.01) and left-ventricular wall thickness (2.82 ± 0.16 vs. 1.98 ± 0.14 mm; n = 16, P < 0.01), whereas the HO inhibitor, chromium mesoporphyrin, exacerbated hypertrophy and cardiac lesions. The suppression of cardiac hypertrophy was accompanied by a robust increase in HO-1, HO activity, cyclic guanosine monophosphate (cGMP), ferritin and the total antioxidant capacity, whereas 8-isoprostane, NF-κB, JNK, AP-1, TGF-β, fibronectin and collagen-I were significantly abated. Correspondingly, histopathological parameters that depict progressive cardiac damage, including fibrosis, interstitial/perivascular collagen deposition, scarring, muscle-fiber thickness, muscular hypertrophy and coronary-arteriolar thickening were abated. Our study suggests that upregulating the HO system lowers blood pressure, potentiates the antioxidant status in tissues, suppresses oxidative stress/mediators such as NF-κB, AP-1 and cJNK, and suppresses the mobilization of ECM proteins like TGF-β, collagen and fibronectin, with corresponding reduction of cardiac histopathological lesion and hypertrophy.Keywords
This publication has 61 references indexed in Scilit:
- Interaction Among Heme Oxygenase, Nuclear Factor-κB, and Transcription Activating Factors in Cardiac Hypertrophy in HypertensionHypertension, 2008
- Association between HMOX-1 genotype and cardiac function during exerciseApplied Physiology, Nutrition, and Metabolism, 2008
- Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertensionJournal Of Hypertension, 2008
- Pharmacological and Clinical Aspects of Heme OxygenasePharmacological Reviews, 2008
- Left Ventricular Hypertrophy in Hypertensive AdolescentsHypertension, 2007
- Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Selective Regulation of Blood Pressure by Heme Oxygenase-1 in HypertensionHypertension, 2002
- Haeme oxygenase-1 and cardiac anaphylaxisBritish Journal of Pharmacology, 2001
- Heme Oxygenase-1 Is Upregulated in the Kidney of Angiotensin II–Induced Hypertensive RatsHypertension, 2000
- Anesthetic management for a patient with acute intermittent porphyria treated with heme arginateJournal of Anesthesia, 1999